Valrubicin (valrubicin)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Valrubicin, a semisynthetic anthracycline antibiotic, is an antineoplastic agent.
USES: Valrubicin is used to treat bladder cancer. The usual treatment for bladder cancer is surgery. However, if you and your doctor decide that the risk of surgery is greater than its benefit or that surgery may be delayed, this medication may be used as part of your treatment.
This medication belongs to a class of drugs known as anthracyclines and works by slowing or stopping the growth of cancer cells. This medication may not cure your cancer. Delaying surgery could lead to a more serious illness (metastatic cancer).
Discuss the risks and benefits of this medication with your doctor.
Generic name: valrubicin
Pronunciation: (val-REWB-eh-sin)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Valrubicin
Indications
The following indications are listed for Valrubicin:
- Malignant Tumor Of Urinary Bladder
Also known as: Bladder Cancer, Bladder Carcinoma, Bladder Malignancy, Malignant Neoplasm Of Bladder.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
Because systemic exposure to valrubicin is minimal following intravesical administration of the drug in patients with an intact bladder mucosa, the potential for drug interactions is low. The possibility of clinically important drug interactions must be considered in patients with systemic exposure to valrubicin (e.g., inadvertent systemic administration of the drug, bladder rupture or perforation in patients receiving intravesical therapy with the drug). Formal studies to evaluate drug interactions with valrubicin have not been performed to date.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Although there are no adequate and controlled studies to date in humans, valrubicin has been shown to be embryotoxic and teratogenic in animal studies. Reproduction studies in rats using daily doses of valrubicin 12 mg/kg IV (about one-sixth the recommended human intravesical dose on a mg/m2 basis) administered during fetal development caused fetal malformations. Administration of valrubicin 24 mg/kg IV (about one-third the recommended human intravesical dose on a mg/m2 basis) to rats resulted in numerous, severe abnormalities in the skull and skeleton of the developing fetuses, an increase in fetal resorptions, and a decrease in viable fetuses. Animal studies to evaluate the effects of intravesical valrubicin on fetal development have not been performed to date.
Valrubicin can cause fetal harm if a pregnant woman is exposed to the drug systemically (as could occur in the case of bladder perforation during intravesical valrubicin therapy), and the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus. If the drug is used during pregnancy or if the patient becomes pregnant while receiving the drug, the patient should be informed of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with valrubicin. The manufacturer also states that men should refrain from engaging in procreative activities during therapy with valrubicin. All sexually active male and female patients of childbearing potential must use an effective method of contraception during valrubicin therapy.
It is not known whether valrubicin is distributed in milk. Because valrubicin is highly lipophilic, and because of the potential for serious adverse reactions to valrubicin in nursing infants, nursing should be discontinued before the initiation of and during valrubicin therapy.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.